<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773253</url>
  </required_header>
  <id_info>
    <org_study_id>Allergan cervical dystonia</org_study_id>
    <nct_id>NCT00773253</nct_id>
  </id_info>
  <brief_title>Botox for Cervical Dystonia Following EMG Mapping</brief_title>
  <official_title>Pre-injection, Multi-channel EMG Mapping to Optimize Botulinum Toxin Type A Efficacy in Cervical Dystonia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine how to improve treatment of patients with cervical
      dystonia who have not been helped with standard Botox injections. This study is for patients
      with cervical dystonia who have not benefited from treatment with Botox using conventional
      &quot;single lead electromyographic (EMG) techniques&quot; for injection. The study aim is to see if
      these patients may have significantly more benefit if their Botox is injected into muscles
      that have been chosen with a multi-channel EMG mapping study of the neck prior to Botox
      injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common type of primary late-onset dystonia is cervical dystonia. Botulinum toxin A
      (BTX-A) injections are a safe and effective treatment for cervical dystonia in a majority of
      patients, however, a significant minority of patients (between 15 and 25%) have a suboptimal
      response to Botulinum toxin therapy. It is unclear why some patients do not respond maximally
      to neurotoxin therapy.

      Studies using needle electromyographic &quot;mapping&quot; in the evaluation of cervical dystonia have
      revealed that clinical examination alone is insufficient for determining which muscles
      contribute to the dystonic movement. When compared to needle electromyography (EMG) &quot;mapping
      studies&quot;, experienced movement disorders specialists correctly identify only 59% of active
      muscles and believe that 25% of muscles which upon EMG evaluation are found to be quiescent,
      are involved in the dystonia. The selection of incorrect muscles for injection of Botulinum
      toxin may explain why some patients have a sub-optimal response.

      This study seeks to measure outcomes when the muscles involved in dystonia are identified
      using &quot;mapping&quot; via an 8-12 channel EMG. In the proposed study, the most involved/active
      dystonic muscles will be correctly identified through simultaneous 8-12 channel mapping
      resulting in a more informed injection strategy, which may improve response to Botulinum
      toxin A treatment as compared to single lead EMG based injections. This study changes routine
      clinical care only by adding the step of studying the muscles of the neck with simultaneous
      EMG mapping to allow a more objective injection strategy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)</measure>
    <time_frame>pre-injection, week 16, 20, 36, and 40</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale</measure>
    <time_frame>48 weeks</time_frame>
    <description>Mean Percentage change in Toronto Western Spasmodic Torticollis Rating Scale. This scale ranges from 0 (normal) to 85 (very severe).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>standard EMG-guided Botox injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-channel EMG-guided Botox injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.</description>
    <arm_group_label>standard EMG-guided Botox injection</arm_group_label>
    <arm_group_label>Multi-channel EMG-guided Botox injection</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female subjects, 18 to 75 years of age.

          -  Ability to follow study instructions and complete all required visits.

          -  Subject meets diagnostic criteria for idiopathic primary cervical dystonia.

          -  Subject has at least moderate severity Cervical Dystonia, with a baseline rating of at
             least 30 on the total TWSTRS and at least 15 on the TWSTRS motor severity subsection.

          -  Patients have had a suboptimal response to 2 previous Botulinum toxin injections at an
             outside facility.

          -  Patients will not have received Botulinum toxin within 16 weeks of the start of the
             study.

          -  In order to not confound the clinical response to BTX-A injections, all patients
             enrolled must have been on a stable medication regimen for 30 days. If they are not on
             medication at the initiation of the study, they will not be started on medication.
             Patients must be on the same medication regimen through the entire study including
             assessment of both single lead EMG based injections and &quot;mapping&quot; based injections.
             Medications cannot be stopped during the study to avoid confounding the clinical
             response to BTX-A.

        Exclusion Criteria:

          -  Known allergy or sensitivity to any of the components in BTX-A.

          -  Uncontrolled clinically significant medical condition other than the condition under
             evaluation

          -  Females with a positive pregnancy test, or who are breast-feeding, planning a
             pregnancy during the study, who think that they may be pregnant at the start of the
             study or females of childbearing potential who are unable or unwilling to use a
             reliable form of contraception during the study.

          -  Participation in another medication or device study or within 3 months of enrollment
             in this study.

          -  Patients know to have a positive frontalis test or have previously tested positive for
             the presence of BTX-A antibodies will be excluded.

          -  Any known evidence of cervical contractures or significant spinal deformity.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham A. Glass, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <results_first_submitted>February 15, 2011</results_first_submitted>
  <results_first_submitted_qc>September 9, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 13, 2011</results_first_posted>
  <last_update_submitted>September 9, 2011</last_update_submitted>
  <last_update_submitted_qc>September 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dystonia</keyword>
  <keyword>cervical dystonia</keyword>
  <keyword>Botox</keyword>
  <keyword>idiopathic primary cervical dystonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard EMG Guided Injections Then Multi-channel Injections</title>
          <description>All patients will undergo injection using conventional single channel (standard)EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.</description>
        </group>
        <group group_id="P2">
          <title>Multi-channel EMG-guided Botox Injection Then Standard EMG Inj</title>
          <description>Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel (standard) EMG-guided Botox, depending on which group they are assigned in the cross-over design.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (Week 0-24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Frontalis Test Negative</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (Week 24-48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard EMG Guided Injections Then Multi-channel</title>
          <description>All patients will undergo injection using conventional single channel EMG-guided technique. This will be used as a baseline for multi-channel mapping-based injections. Patients will be randomized to undergo single-channel vs. multi-channel assessment upon study entry and will then cross over to the alternate arm.</description>
        </group>
        <group group_id="B2">
          <title>Multi-channel EMG-guided Botox Injection Then Single Channel</title>
          <description>Patients will receive multi-channel EMG-guided Botox injection before or after they have been treated with single-channel EMG-guided Botox, depending on which group they are assigned in the cross-over design.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="5.2"/>
                    <measurement group_id="B2" value="54.7" spread="5.1"/>
                    <measurement group_id="B3" value="55.4" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre- and Post-injection Toronto Western Spasmodic Torticollis Rating Scale(TWSTRS): Global Clinical Impression Scale (GCI); Visual Analog Scale(VAS)</title>
        <time_frame>pre-injection, week 16, 20, 36, and 40</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale</title>
        <description>Mean Percentage change in Toronto Western Spasmodic Torticollis Rating Scale. This scale ranges from 0 (normal) to 85 (very severe).</description>
        <time_frame>48 weeks</time_frame>
        <population>All participants that completed all phases of the study</population>
        <group_list>
          <group group_id="O1">
            <title>Standard EMG Guided Injections</title>
            <description>All patients underwent single channel (standard)EMG-guided technique.</description>
          </group>
          <group group_id="O2">
            <title>Multi-channel EMG-guided Botox Injection</title>
            <description>Patients will receive multi-channel EMG-guided Botox injection.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percentage Change in Total Toronto Western Spasmodic Torticollis Rating Scale</title>
          <description>Mean Percentage change in Toronto Western Spasmodic Torticollis Rating Scale. This scale ranges from 0 (normal) to 85 (very severe).</description>
          <population>All participants that completed all phases of the study</population>
          <units>percent change in units on the scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="20.8"/>
                    <measurement group_id="O2" value="23.5" spread="15.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard EMG Guided Injections</title>
          <description>All patients underwent single channel (standard)EMG-guided technique.</description>
        </group>
        <group group_id="E2">
          <title>Multi-channel EMG-guided Botox Injection</title>
          <description>Patients will receive multi-channel EMG-guided Botox injection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient received single channel injection, but did not get multi-channel injection because the frontalis test showed immunity to botulinum toxin indicating no possibility of clinical benefit. This is an exclusion criterion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Graham A. Glass, MD</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-353-2311</phone>
      <email>Graham.Glass@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

